Honghuaruyi Wan for Endometriosis Dysmenorrhea

Endometriosis Clinical Trial

Official title:

Beijing University of Chinese Medicine

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04942015
• Other study ID #: HHRYW2021-05
• Status: Not yet recruiting
• Phase: Phase 4
• Start date: June 21, 2021
• Est. completion date: December 31, 2023

Study information

• Verified date: June 2021
• Source: Beijing University of Chinese Medicine
• Contact: Mei Han
• Phone: +86 10 64287002
• Email: hanmeizoujin[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Endometriosis is a common gynecological disease. It is a gynecological disease caused by the growth and reproduction of the endometrium beyond the surface of the uterine tissue and organs, which causes recurrent abdominal pain, infertility and other main symptoms. The recurrence of endometriosis and the side effects of medication have troubled clinicians and patients for a long time and the search for new drugs is going on all the time. Honghuaruyi Wan is the traditional Tibetan prescription, clinical research has proved that Honghuaruyi Wan can significantly reduce risk mouse dysmenorrhea caused by oxytocin, improve dysmenorrhea model of mice body torsion times and improve the estrogen and progestogen operator Netherlands rat pituitary estradiol and prolactin level, at the same time also can reduce the amount of TNF alpha, thus improving endometriosis dysmenorrhea. In this study, the therapeutic effects of Honghuaruyi Wan provided by Tibet Qizheng Tibetan Medicine Co.,Ltd on secondary dysmenorrhea in patients with endometriosis was evaluated clinically. A multi-center, randomized, double-blind, placebo-controlled clinical trial was designed to provide evidence-based medical evidence for Honghuaruyi Wan in the treatment of endometriosis dysmenorrhea. In the design of this trial, the therapeutic effects and safety of Honghuaruyi Wan in the treatment of dysmenorrhea secondary to endometriosis were evaluated with Honghuaruyi Wan in the treatment group and placebo in the control group.

Description:

Endometriosis (EM) is a common gynecological disease at present. It is a gynecological disease caused by the growth and reproduction of the endometrium on the surface of tissues and organs beyond the uterine covering surface, resulting in recurrent abdominal pain and infertility. The pathogenesis of endometriosis may be related to female endocrine dysfunction and abnormal levels of estrogen and progesterone in the body. Its clinical symptoms mainly include dysmenorrhea, chronic pelvic pain and sexual pain. The recurrence of endometriosis and the side effects of medication have troubled clinicians and patients for a long time. The search for new drugs has been going on. Honghuaruyi Wan is a traditional Tibetan prescription, which is made by addition and subtraction on the basis of the traditional and classic Tibetan medicine prescription "25 Wei Guijiu Wan". Its main ingredients are: Honghua,Xihonghua,Taoerqi,Kezi,Zangqiancao,Rougui,Baxiaga,Zangmuxiang,Yuansuiguo,Jiangxiang,X iongdanfen,Zangzicao,Guangmingyan,Ximalayazimoli,Bangga,Hujiao,Huasherou,Aizijin,Yuganzi,Shaj igao,Naosha,Zicaorong,Gouqizi,Chenxiang,Huoxiao. It has the effects of dispelling wind-evil and relieving pain, regulating menstrual blood and removing spots. It can be used for vaginitis, cervical erosion, irregular menstruation, dysmenorrhea and other common gynecological diseases. The main medicinal ingredients of Honghuaruyi Wan are Honghua ,Taoerqi and Zanghonghua, which have the effects of relieving pain, regulating menstruation and blood and dispersing knots. Some clinical studies have shown that the basic prescription of Honghuaruyi Wan have a significant effect on the improvement of dysmenorrhea, which can significantly reduce the incidence of dysmenorrhea caused by oxytocin in mice, and improve the number of body twisting in dysmenorrhea model mice. Other clinical studies have shown that Honghuaruyi Wan can improve estradiol and prolactin levels of pituitary gland in rats with estrogen and progesterone, as well as reduce TNF-α levels, thus improving endometriosis dysmenorrhea. For women of childbearing age who do not have fertility requirements, pain is the most important clinical symptom that needs to be addressed, especially with progressive dysmenorrhea. Therefore, in this study, the therapeutic effects of Honghuaruyi Wan, provided by Tibet Qizheng Tibetan Medicine Co.,Ltd, on the secondary dysmenorrhea of patients with endometriosis was evaluated clinically. A multi-center, randomized, double-blind, placebo-controlled clinical trial was designed to provide evidence-based medical evidence for Honghuaruyi Wan in the treatment of endometriosis dysmenorrhea. In the design of this trial, the therapeutic effects and safety of Honghuaruyi Wan in the treatment of dysmenorrhea secondary to endometriosis were evaluated with Honghuaruyi Wan in the treatment group and placebo in the control group.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 164
• Est. completion date: December 31, 2023
• Est. primary completion date: May 31, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Meet the diagnostic criteria for endometriosis and have dysmenorrhea VAS score =4 points;

2. Age 18 to 45;

3. Regular menstrual cycle (28±7 days);

4. Not pregnant at the time of seeing a doctor and no pregnancy plan during the medication, can insist on contraception;

5. No pelvic nodules or adnexal masses, or pelvic nodules or adnexal masses =4cm;

6. CA125 is normal or slightly elevated (below 200U/ml).

7. Patients who voluntarily signed the informed consent and had conditional follow-up.

Exclusion Criteria:

1. Patients who have known to have malignancies of reproductive organs or other malignancies;

2. Suffering from serious diseases or mental diseases such as cardiovascular, cerebrovascular, liver, kidney or hematopoietic system;

3. Uterine fibroids (=3cm) and adenomyosis (uterine over 6 weeks of gestation, the reference value of uterine tridiameter at 6 weeks is 12cm, 7.5cm, 4.5cm);

4. Those who received hormone drug therapy within 3 months before enrollment;

5. lactating patients.

Related Conditions & MeSH terms

• Dysmenorrhea
• Endometriosis

Intervention

Drug:
• Honghuaruyi Wan
Honghuaruyi Wan is the traditional Tibetan prescription, clinical research has proved that Honghuaruyi Wan can significantly reduce risk mouse dysmenorrhea caused by oxytocin, improve dysmenorrhea model of mice body torsion times and improve the estrogen and progestogen operator Netherlands rat pituitary estradiol and prolactin level, at the same time also can reduce the amount of TNF alpha, thus improving endometriosis dysmenorrhea.(Pill (15 pills/plate ×2 plates/box))
• Placebo of Honghuaruyi Wan
Honghuaruyi Wan simulation agent. Made of starch,dextrin and edible pigment from Tibet Qizheng Tibetan Medicine Co.,Ltd. ( Pill (15 pills/plate ×2 plates/box))

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Beijing University of Chinese Medicine

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Visual Analogue Scale/Score (VAS)	Draw a horizontal line of 10 cm on the paper. One end of the horizontal line is 0, indicating no pain.The other end is 10, which means severe pain; The part between the two ends represents different levels of pain. A higher score means a worse outcome.	Baseline through 6th consecutive menstrual cycle. (One cycle = 28±7days)
Primary	Endometriosis Health Profle-5(EHP-5)	The core questionnaire contains 5 questions,every question has 5 answers:Never=0,Very few=1,Sometimes=2,Often=3,Always=4. The minimum and maximum values are between 0 to 20 and a higher value means a worse outcome.	Baseline through 6th consecutive menstrual cycle. (One cycle = 28±7days)
Primary	The 5-level EQ-5D version(EQ-5D-5L)	There are 6 questions in the scale,the first 5 questions has 5 answers:No=0, A little bit=1, Moderate=2, Serious=3 Very serious=4. The minimum and maximum values are between 0 to 20 and a higher value means a worse outcome. The 6th question is about the status of the day visited. The minimum and maximum scores are between 0 to 100 and a higher value means a better outcome.	Baseline through 6th consecutive menstrual cycle. (One cycle = 28±7days)
Secondary	Visual Analogue Scale/Score (VAS) of the maximum non-menstrual pelvic pain	Draw a horizontal line of 10 cm on the paper. One end of the horizontal line is 0, indicating no pain.The other end is 10, which means severe pain; The part between the two ends represents different levels of pain. A higher score means a worse outcome.	Baseline through 6th consecutive menstrual cycle. (One cycle = 28±7days)
Secondary	The number of ibuprofen sustained-release capsules (or other NSAIDs) used	The number of ibuprofen sustained-release capsules (or other NSAIDs) used	Baseline through 6th consecutive menstrual cycle. (One cycle = 28±7days)
Secondary	Number of days off for staff/students due to dysmenorrhea	Number of days off for staff/students due to dysmenorrhea	Baseline through 6th consecutive menstrual cycle. (One cycle = 28±7days)
Secondary	The maximum diameter of the uterus	The diameter of the uterus will be measured by B ultrasonic	Baseline, After treatment (3rd menstrual cycle). (One cycle = 28±7days)
Secondary	The maximum diameter of the cysts	The diameter of the cysts will be measured by B ultrasonic	Baseline, After treatment (3rd menstrual cycle). (One cycle = 28±7days)